MetaVia Inc. Files 8-K for Regulation FD Disclosure
Ticker: MTVA · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Metavia INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulation-fd, filing
TL;DR
MetaVia Inc. filed an 8-K on Jan 10, 2025, for a Reg FD disclosure. Check for material updates.
AI Summary
On January 10, 2025, MetaVia Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure and includes Financial Statements and Exhibits. The company, previously known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc., is incorporated in Delaware and its principal executive offices are located in Cambridge, Massachusetts.
Why It Matters
This 8-K filing indicates MetaVia Inc. is making a public disclosure under Regulation FD, which could contain material information relevant to investors.
Risk Assessment
Risk Level: low — This filing is a routine disclosure and does not appear to contain any immediate negative or positive financial events.
Key Players & Entities
- MetaVia Inc. (company) — Registrant
- NeuroBo Pharmaceuticals, Inc. (company) — Former company name
- Gemphire Therapeutics Inc. (company) — Former company name
- January 10, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for MetaVia Inc.?
The primary purpose of this 8-K filing is for a Regulation FD Disclosure and to include Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on January 10, 2025.
What were MetaVia Inc.'s previous company names?
MetaVia Inc. was formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc.
In which state is MetaVia Inc. incorporated?
MetaVia Inc. is incorporated in Delaware.
What is the business address of MetaVia Inc.?
The business address of MetaVia Inc. is 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.
Filing Stats: 668 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2025-01-10 08:30:29
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share MTVA The Nasdaq Stock Mar
Filing Documents
- mtva-20250110x8k.htm (8-K) — 46KB
- mtva-20250110xex99d1.htm (EX-99.1) — 25KB
- mtva-20250110x8k001.jpg (GRAPHIC) — 9KB
- mtva-20250110xex99d1g001.jpg (GRAPHIC) — 101KB
- mtva-20250110xex99d1g002.jpg (GRAPHIC) — 194KB
- mtva-20250110xex99d1g003.jpg (GRAPHIC) — 158KB
- mtva-20250110xex99d1g004.jpg (GRAPHIC) — 96KB
- mtva-20250110xex99d1g005.jpg (GRAPHIC) — 194KB
- mtva-20250110xex99d1g006.jpg (GRAPHIC) — 38KB
- mtva-20250110xex99d1g007.jpg (GRAPHIC) — 183KB
- mtva-20250110xex99d1g008.jpg (GRAPHIC) — 37KB
- mtva-20250110xex99d1g009.jpg (GRAPHIC) — 132KB
- mtva-20250110xex99d1g010.jpg (GRAPHIC) — 88KB
- mtva-20250110xex99d1g011.jpg (GRAPHIC) — 128KB
- mtva-20250110xex99d1g012.jpg (GRAPHIC) — 105KB
- mtva-20250110xex99d1g013.jpg (GRAPHIC) — 88KB
- mtva-20250110xex99d1g014.jpg (GRAPHIC) — 66KB
- mtva-20250110xex99d1g015.jpg (GRAPHIC) — 96KB
- mtva-20250110xex99d1g016.jpg (GRAPHIC) — 104KB
- 0001558370-25-000100.txt ( ) — 2662KB
- mtva-20250110.xsd (EX-101.SCH) — 3KB
- mtva-20250110_lab.xml (EX-101.LAB) — 16KB
- mtva-20250110_pre.xml (EX-101.PRE) — 10KB
- mtva-20250110x8k_htm.xml (XML) — 5KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure . On January 10, 2025, MetaVia Inc. (the "Company") posted an updated corporate presentation to its website at https://www.metaviatx.com/events-presentations/presentations, which the Company may use from time to time in communications or conferences. A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K (this "Report"). Information contained on or accessible through any website reference in the corporate presentation is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the corporate presentation is as inactive textual references only. Exhibit 99.1 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements. The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company's submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Presentation dated January 2025. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. METAVIA INC. Date: January 10, 2025 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer